Are Hospitals Ready for Alzheimer’s Treatment Approval?
HIT Consultant
MARCH 19, 2023
John Showalter, MD, Chief Product Officer at Linus Health The FDA’s recent accelerated approval of Leqembi was welcome news across the Alzheimer’s community. However, few health systems, medical practices, or providers are prepared for the extraordinary public interest in a treatment for Alzheimer’s disease – especially not one targeting mild cognitive impairment (MCI) and early dementia due to Alzheimer’s disease – that is likely headed their way soon.
Let's personalize your content